MET fusions and splicing variants is a strong adverse prognostic factor in astrocytoma, isocitrate dehydrogenase mutant.

Lingyu LiuKe-Nan ZhangZheng ZhaoGuanzhang LiRui-Chao ChaiZhuoqun LiXing LiuJing ChenTao Jiang

Published in: Brain pathology (Zurich, Switzerland) (2023)

Liu et al. describe the adverse prognostic role of MET fusions and splicing variants in astrocytoma, isocitrate dehydrogenase mutant. On this basis, MET fusions and splicing variants was suggested to be a biomarker for the diagnosis of high-grade astrocytoma, isocitrate dehydrogenase mutant.

Keyphrases

wild type
prognostic factors
copy number
high grade
tyrosine kinase
low grade
emergency department
adverse drug
dna methylation